Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Psilocybin is a serotonergic psychedelic found in “magic mushrooms” with a putative therapeutic potential for treatment-resistant depression, anxiety, obsessive-compulsive disorder, and addiction. In rodents, psilocybin acutely induces plasticity-related immediate early genes in cortical tissue; however, studies into the effects on subcortical regions, of different doses, and the subsequent translation of corresponding proteins are lacking. Methods: We examined the acute effects of a single administration of psilocybin (0.5–20 mg/kg) on the expression of selected genes in the prefrontal cortex and hippocampus. In total, 46 target genes and eight reference genes were assessed using real-time quantitative polymerase chain reaction. Corresponding protein levels of the three most commonly regulated genes were assessed using Western blotting. Results: In the prefrontal cortex, psilocybin increased the expression of Cebpb, c-Fos, Dups1, Fosb, Junb, Iκβ-α, Nr4a1, P11, Psd95, and Sgk1, and decreased the expression of Clk1. In the hippocampus, psilocybin strongly increased the expression of Arrdc2, Dusp1, Iκβ-α, and Sgk1 in a dose-dependent manner, and decreased the expression of Arc, Clk1, Egr2, and Ptgs2. Protein levels of Sgk1, Dusp1, and Iκβ-α showed only partial agreement with transcriptional patterns, stressing the importance of assessing downstream translation when investigating rapid gene responses. Conclusion: The present study demonstrates that psilocybin rapidly…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psilocybin stimulated the expression of IEGs in the PFC, and induced stimulating and inhibiting effects in the hippocampus (55).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [55]
In the citing paper
“Moreover, in both areas, most IEGs were affected in a dose-dependent manner, with higher doses inducing more stimulation of gene expression (55).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [55]
In the citing paper
“A single dose of psilocybin (0.5, 1, 2, 4, 8, 14, 20 mg/kg, i.p.) administered to rats (n = 10) altered the expression of plasticity-promoting genes in the prefrontal cortex (PFC) and hippocampus, 90 min after treatment (55).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [55]
In the citing paper
“Findings from in vivo studies investigating acute effects of a single dose of 5-MeO-DMT, DMT, psilocybin, and LSD (37%) suggest altered cellular plasticity of structural and functional nature (54–60).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [55]
In the citing paper
“preclinical evidence suggests a dose-dependent effect on increases in the expression of some neuroplasticity-related genes induced by serotonergic psychedelics [73–75]”
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“This incongruity is not surprising considering that translation is regulated by a plethora of post-transcriptional mechanisms, and the general correlation between transcriptional and translational responses is usually modest (Schwanhausser et al., 2011).”
BackgroundA Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · cited 1×
“2 from humans to rats (Nair and Jacob, 2016), resulting in a corresponding dose of ∽2 mg/kg for rats.”
BackgroundShared Principles in NF-κB Signaling
Hayden, M. S., & Ghosh, S. (2008) · Cell · doi:10.1016/j.cell.2008.01.020 · Cited by 4,494
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Pazos, A., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855 · cited 3×
“c-Fos has been widely used as a marker of neuronal activity (Kovacs, 1998), and the present findings therefore indicate that psilocybin induces strong neuronal activation in the PFC, but not in the HIP, consistent with electrophysiological studies and receptor distributions between regions (Aghajanian and Marek, 1999;…”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 2×
“In humans, these acute effects are followed by long-lasting positive effects on clinical symptoms (Bogenschutz et al., 2015; Carhart-Harris et al., 2016, 2018; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2014, 2017; Moreno et al., 2006; Ross et al., 2016) and psychological features (Erritzoe et al.”
BackgroundNeurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606 · cited 1×
“, 1985) also implicated in the pathophysiology of depression (Price and Drevets, 2010).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
MAPK cascade signalling and synaptic plasticity
Thomas, G. M., & Huganir, R. L. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1346 · Cited by 1,454 · cited 1×
“Paradoxically, each of these genes has been linked to both promotion and deterioration of synaptic plasticity, possibly depending on whether the activation is acute or chronic (Alberini et al., 1994; Anacker et al., 2013; Bridi et al., 2017; Duric et al., 2010; Jeanneteau et al., 2010, 2018; Thomas and Huganir, 2004).”
BackgroundPSD-95 Involvement in Maturation of Excitatory Synapses
El-Husseini, A. E.-D., Schnell, E., Chetkovich, D. M., Nicoll, R. A., & Bredt, D. S. (2000) · Science · doi:10.1126/science.290.5495.1364 · Cited by 1,303 · cited 1×
“, 2003; Lopez-Gimenez and Gonzalez-Maeso, 2018); (c) transcriptional regulation of synaptic plasticity (Alberini, 2009; El-Husseini et al., 2000); or (d) transcriptional effects of anti-depressive treatments (Bramham et al.”
Background
Research works printed but not linked: 2
- Almaula N, 1996, Mol Pharmacol, 50, 34
- Johnson MP, 1994, Mol Pharmacol, 45, 277
Cited by
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
“, 2012), supporting the idea that psychedelics have neuroplastic and neurogenic properties (Catlow et al., 2013; Jefsen et al., 2020; Ly et al., 2018).”
BackgroundTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Similarly, DOI failed to enhance expression of Arc in the hippocampus [106].”
BackgroundInfluentialNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Davoudian, P. A., Shao, L.-X., & Kwan, A. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00637 · Cited by 129
Aaronson, S. T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H. A., & Suppes, T. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4685 · Cited by 114
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Du, Y., Li, Y., Zhao, X., Yao, Y., Wang, B., Zhang, L., & Wang, G. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002647 · Cited by 94
“[17,40] BDNF and mTOR signaling are crucial in fear extinction.”
BackgroundKozłowska, U., Nichols, C. D., Wiatr, K., & Figiel, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15509 · Cited by 89
“There are several known genes involved in synaptic plasticity whose expression is changed in response to psychedelics (Jefsen et al., 2021; Nichols & Sanders- Bush, 2004).”
BackgroundPsychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“Other recent work highlights other genes exhibiting expression changes following psilocybin treatment (Donovan et al., 2021; Jefsen et al., 2021).”
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“For example, c- Fos expression in the cortex, but not the hippocampus is commonly observed following administration of psychedelics such as DOI and psilocybin (Jefsen et al., 2021; Leslie et al., 1993).”
BackgroundWeiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“In particular, psilocybin was shown to upregulate plasticity-related genes (including Cebpb, c-Fos, Dups1, Fosb, Junb, I κβ - α , Nr4a1, P11, Psd95 and Sgk1) in the same areas in a dose-dependent fashion [54].”
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“a rapid dose dependent preferential modulation of plasticityrelated genes in the PFC compared to the hippocampus in rats (183).”
BackgroundZhao, X., Du, Y., Yao, Y., Dai, W., Yin, Y., Wang, G., Li, Y., & Zhang, L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249436 · Cited by 71
“A study demonstrated that psilocybin rapidly induces the expression of genes related to neuroplasticity in the PFC and hippocampus; our results were similar to theirs (Jefsen et al., 2021).”
ResultChen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Fadahunsi, N., Lund, J. T., Breum, A. W., Mathiesen, C. V., Larsen, I. B., Knudsen, G. M., Klein, A. B., & Clemmensen, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02103-9 · Cited by 54
“Based upon these data and existing literature (which supports the use of 1–3mg/kg in rodents [35], we selected 3mg/ kg as the dose for subsequent metabolic in vivo studies.”
Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states
Muir, J., Lin, S., Aarrestad, I. K., Daniels, H. R., Ma, J., Tian, L., Olson, D. E., & Kim, C. K. (2024) · Science · doi:10.1126/science.adl0666 · Cited by 55
Magaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
“Psilocybin also enhanced the expression of genes that are related to neuroplasticity [189].”
BackgroundDesouza, L. A., Benekareddy, M., Fanibunda, S. E., Mohammad, F., Janakiraman, B., Ghai, U., Gur, T., Blendy, J. A., & Vaidya, V. A. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.790213 · Cited by 44
“Fos may also function at enhancer elements to coordinate global activity-dependent gene transcription (Malik et al., 2014; Joo et al., 2016).”
BackgroundRole of Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) in Immune and Inflammatory Diseases
Bian, X., Xue, H., Jing, D., Wang, Y., Zhou, G., & Zhu, F. (2023) · Inflammation · doi:10.1007/s10753-023-01857-8 · Cited by 51
“Psilocybin has the potential to alleviate depression by increasing the expression of SGK1 [82].”
BackgroundCatalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 37
“A single administered dose of psilocybin induces changes in neural plasticity–related gene expression in the hippocampus and PFC (Jefsen et al., 2020), and 5-MeO-DMT induces large-scale changes in protein expression in cultured human brain tissue (Dakic et al.”
BackgroundInfluentialα-Arrestins and Their Functions: From Yeast to Human Health
Zbieralski, K., & Wawrzycka, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094988 · Cited by 47
“Similarly, ARRDC2 mRNA has been observed to be strongly upregulated in the hippocampus of rats upon stimulation with a single high dose of psilocybin, which is a 5-HT receptor agonist and a potential drug in the treatment of psychiatric disorders [187].”
BackgroundShahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02477-w · Cited by 40
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 49
“extent, in the hippocampus of rats [79].”
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 40
“The drug has been shown to modulate glutamatergic activity in prefrontal circuits [87, 88], reduce in fl ammatory activity [89 – 91], induce gene expression relevant for neuroplasticity pathways [92], and promote neuronal growth [17, 93].”
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 42
“Several studies have found that psilocybin affects expression of several transcription factors and plasticity-related genes in the rat PFC and hippocampus (González-Maeso et al., 2003; 2007; Jefsen et al., 2021).”
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
The potential of psychedelics for the treatment of Alzheimer's disease and related dementias
Winkelman, M., Szabó, A., & Frecska, E. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.003 · Cited by 35
Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy
Harrison, T. R., Faber, S. C., Zare, M., Fontaine, M., & Williams, M. T. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433423 · Cited by 29
“Psychedelics are also shown to support neuroplasticity, neurogenesis, and synaptogenesis, reshaping brain cells and rewiring pathways (Du et al. 2023; Jefsen et al. 2021; Ly et al. 2018; Shao et al. 2021).”
Epigenetic Mechanisms of Rapid-Acting Antidepressants
Inserra, A., Campanale, A., Rezai, T., Romualdi, P., & Rubino, T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03055-y · Cited by 27
“In accordance, CEBP2 together with several other neuroplasticity-related genes is dose-dependently transcriptionally modulated in the PFC following psilocybin administration [191].”
BackgroundKolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka‐Wasylewska, M., Bugno, R., Hogendorf, A. S., Bojarski, A. J., & Faron‐Górecka, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06644-3 · Cited by 29
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
“A presumably sub-perceptual dose of DMT, 1 mg/kg, increased functional plasticity in rat cortical slices [43], whereas a perceptual dose of 4 mg/kg of psilocybin was required to induce neuroplasticity-related changes in gene expression in rat PFC [87].”
BackgroundPsilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
“Created with MedPeer (www.medpeer.cn). neuroplasticity-related proteins (including BDNF) and gene expression (e.g., c-Fos, Junb, Dusp1, I κβ - α ) (Takei et al., 2004; Jefsen et al., 2021; Davoudian et al., 2023).”
BackgroundRapid, biochemical tagging of cellular activity history in vivo
Zhang, R., Anguiano, M., Aarrestad, I. K., Lin, S., Chandra, J., Vadde, S. S., Olson, D. E., & Kim, C. K. (2024) · Nature Methods · doi:10.1038/s41592-024-02375-7 · Cited by 25
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
“These results are generally consistent with the findings of Jefsen et al. (2021), who found that in rats, psilocybin (0.5–20 mg/kg, i.p.) rapidly regulates a variety of plasticity-related genes in the prefrontal cortex (PFC) and hippocampus in a dose-dependent manner.”
InfluentialErkizia-Santamaría, I., Horrillo, I., Martínez-Álvarez, N., Pérez-Martínez, D., Rivero, G., Erdozain, A. M., Meana, J. J., & Ortega, J. E. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03421-4 · Cited by 26
“It is reasonable to think that a closer time point would be more suitable for the evaluation of certain molecular pathways targeted by the drug, to unfold the molecular basis of the therapeutic action of psilocybin.”
Domanegg, K., Sommer, W. H., & Meinhardt, M. W. (2023) · Cells · doi:10.3390/cells12060963 · Cited by 24
“In general, psychedelics rapidly induce the transcription of neuroplasticity-related genes [71].”
BackgroundEmerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 24
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114940 · Cited by 23
Lysergic acid diethylamide induces increased signalling entropy in rats’ prefrontal cortex
Savino, A., & Nichols, C. D. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15534 · Cited by 22
“…genes have been reported to be over-expressed upon psychedelics’ administration in rodent models, especially in areas with dense 5-HT 2A receptor expression like the prefrontal cortex (PFC) (Benekareddy et al., 2013; González-Maeso et al., 2003, 2007; Jefsen et al., 2020; Nichols et al., 2003).”
Haniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 22
“…bulk RNA sequencing of hippocampus from rats administered psilocybin 0.5 – 20mg/kg found gene expression changes related to stress response andneuroplasticity mechanisms;notably upregulation of DUSP1, I κβ - α and SGK1, and decrease in EGR2 expression (Jefsen, Elfving, Wegener, & Müller, 2021).”
InfluentialPsychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
“Indeed, one of the mechanisms underlying the rapid and lasting modi fi cation of cytoarchitecture induced by psychedelics is the increase of BDNF levels [127, 128], particularly described in the prefrontal cortex and hippocampus, two cardinal regions for cognitive processes [125, 126].”
Psilocybin as a novel treatment for chronic pain
Askey, T., Lasrado, R., Maiarù, M., & Stephens, G. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17420 · Cited by 22
“People with chronic pain reportedly have a decreased grey matter volume within the PFC (Kang et al., 2019) and reduced functional connectivity within corticolimbic circuits (Vachon-Presseau et al., 2016; Yang & Chang, 2019).”
InfluentialMind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 21
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Moderators of ayahuasca’s biological antidepressant action
de Sousa, G. M., Tavares, V. D. D. O., Galvão, A. C. D. M., de Almeida, R. N., Palhano-Fontes, F., Soares, B. L., Freire, F. A. D. M., Nunes, E. A., Maia‐de‐Oliveira, J. P., Perkins, D., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1033816 · Cited by 26
Benvenuti, F., Colombo, D., Soverchia, L., Cannella, N., Domi, E., & Ciccocioppo, R. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06384-w · Cited by 21
“Additionally, since rodent studies have found that psychedelics can evoke protracted change in the brain structure and induce molecular and cellular adaptations related to neuroplasticity (Cameron et al. 2018; Ly et al. 2018; Jefsen et al. 2021), we south interesting to investigate the effect of psilocybin in a valida…”
BackgroundAcute psilocybin increased cortical activities in rats
Liu, J., Wang, Y., Xia, K., Wu, J., Zheng, D., Cai, A., Yan, H., & Su, R. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1168911 · Cited by 19
“These IEG are involved in various processes such as learning, memory, neuroplasticity, neural reaction to various stimuli, and psychiatric disorders (González-Maeso et al., 2007; Pérez-Cadahía et al., 2011; Leal et al., 2014; Minatohara et al., 2016; Chandra and Lobo, 2017; Duclot and Kabbaj, 2017; Jefsen et al., 2021…”
BackgroundRetractedPsychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 17
“20 For up to a month, just a single dose of psilocybin increases the size and density of dendritic spines in layer V pyramidal neurons in the mouse medial frontal cortex.”
BackgroundHosein, M., Reid, M. J., Walser, S. A., Charney, S., Fonzo, G. A., Lewis, B. R., Yaden, D. B., Suppes, T. M., Cordner, Z. A., & Barrett, F. S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103517 · Cited by 17
“18 In studies of patients with MDD, EEG correlates of increased neuroplasticity have also been observed following psilocybin-administration, relative to placebo.”
Effect of a single psilocybin treatment on Fos protein expression in male rat brain
Funk, D. R., Araujo, J. A., Slassi, M., Lanthier, J., Atkinson, J., Feng, D., Lau, W., Lê, A., & Higgins, G. A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.01.001 · Cited by 16
Lerer, E., Botvinnik, A., Shahar, O., Grad, M., Blakolmer, K., Shomron, N., Lotan, A., Lerer, B., & Lifschytz, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1391412 · Cited by 17
Zhornitsky, S., Oliva, H. N. P., Jayne, L. A., Allsop, A. S., Kaye, A. P., Potenza, M. N., & Angarita, G. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197890 · Cited by 18
“In addition, some presynaptic markers have been shown to be altered by ketamine, but not by psychedelics, such as synapsin-1 and synaptophysin-1 (55, 144).”
BackgroundInfluentialUtility of preclinical models in the study of psilocybin – A comprehensive review
Pedicini, M., & Cordner, Z. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105046 · Cited by 15
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
“Recently, the acute effects of a single administration of psilocy-bin (0.5–20 mg/kg) on the expression of selected genes and corresponding protein levels were assessed in rat brain tissue [100].”
InfluentialIntegrative genomics analysis highlights functionally relevant genes for equine behaviour
Holtby, A. R., Hall, T. J., McGivney, B. A., Han, H., Murphy, K. J., MacHugh, D. E., Katz, L. M., & Hill, E. W. (2023) · Animal Genetics · doi:10.1111/age.13320 · Cited by 14
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
“First, preclinical evidence suggests a dose-dependent effect on increases in the expression of some neuroplasticity-related genes induced by serotonergic psychedelics [73–75], a key proposed therapeutic mechanism [44, 45].”
BackgroundEvaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Fuini, E., Chang, A., Ortiz, R. J., Nasseef, M. T., Edwards, J., Latta, M., Gonzalez, E., Woodward, T. J., Bradshaw, H. B., Axe, B., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1554049 · Cited by 14
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
“Moreover, psilocybin resulted in increased presynaptic density in brain cortex and hippocampus of pigs (Raval et al., 2021) and upregulated expression of plasticity-related genes in rat PFC and hippocampus (Jefsen et al., 2021; Magdalena et al., 2024).”
Beretta, E., Cuboni, G., & Deidda, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125508 · Cited by 12
“…revealed that psilocybin-induced synaptic plasticity in the rat brain may be more pronounced in the prefrontal cortex compared to the hippocampus [230]; moreover, the author showed that neuroplastic gene expression, with corresponding variations in protein levels, might be dose-dependent [230].”
The ABCs of psychedelics: a preclinical roadmap for drug discovery
Kwan, A. C., Mantsch, J. R., & McCorvy, J. D. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.017 · Cited by 12
“Indeed, studies have demonstrated region-speci fi c pro fi le of psychedelic-evoked transcriptional responses as a function of dose in rats [77].”
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models
Adeyinka, D. A., Forsyth, D., Currie, S., & Faraone, N. (2025) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2025.1585367 · Cited by 12
“…gene editing, and circuit-level mapping in animals now make it possible to dissect which genes and pathways are critical for psilocybin’s eects (Jefsen et al., 2021), research can now focus on those involved in mood regulation, neural plasticity, and immune signaling, thus revealing mechanisms…”
mPFC DUSP1 mediates adolescent cocaine exposure‐induced higher sensitivity to drug in adulthood
Wei, X., Chang, J., Cheng, Z., Chen, W., Guo, H., Liu, Z., Mai, Y., Hu, T., Zhang, Y., Cai, Q., et al. (2023) · EMBO Reports · doi:10.15252/embr.202356981 · Cited by 10
“For example, psilocybin strongly upregulates Dusp1 levels in PFC (Jefsen et al , 2020), and synthetic cathinone (substitutes for illicit psychostimulants including cocaine) produces high Dusp1 levels in striatum (Wojcieszak et al , 2019).”
Ghaffarzadegan, R., Karimi, M., Hedayatjoo, B., Behnoud, H., Jasemi, E., Mohammadi, M., Roustaei, S., Razmi, A., & Vaseghi, S. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2428241 · Cited by 10
“It has been shown that psilocybin upregulates the expression level of genes related to neuroplasticity after a short period in rats, particularly in the prefrontal cortex (Jefsen et al. 2021).”
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Chisamore, N., Kaczmarek, E. S., Le, G. H., Wong, S., Orsini, D. K., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00319-8 · Cited by 9
“Psilocybin has also been associated with increased gene expression indicative of neuroplasticity in the rat prefrontal cortex as measured by dendritic spine density [47].”
Liao, C., O'Farrell, E., Weiner, A. M., Qalieh, Y., Savalia, N. K., Girgenti, M. J., Kwan, K. Y., & Kwan, A. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.04.631335 · Cited by 9
“…receptor signaling, and immune response in the neocortex after a single dose of a classic psychedelic such as 2,5-dimethoxy-4-63 iodoamphetamine (DOI) 12, 13, 14, 15 , lysergic acid diethylamide (LSD) 12, 16 , 5-methoxy-N , N - dimethyltryptamine (5-MeO-DMT) 17 , or psilocybin 15, 18, 19 .”
Clarkson, R. D. O., Jabbour, M., Pelayo, D. A., Lara, D., Croix, S. L., Mumman, M., Stukas, S., Anderson, R., Meraz, D., Bangura, A., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111155 · Cited by 8
Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In VitroPreprint
Smedfors, G., Glotfelty, E. J., Kalani, N., Hjelle, C. P., Horntvedt, O., Wellfelt, K., Brodin, A., von Kieseritzky, F., Olson, L., & Karlsson, T. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1321542/v1 · Cited by 8
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
Konstantinou, G., Rosenblat, J. D., Hales, S., Husain, M. I., & Blumberger, D. M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.12.005 · Cited by 7
Syed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 7
Bhagavan, C., Bryson, A., Carter, O. L., Nielsen, G., Berlowitz, D. J., Issak, S., Braat, S., Zaloumis, S. G., Attard, Z., Eleftheriadis, D., et al. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.10042 · Cited by 8
Psilocybin has a narrow therapeutic window as an antidepressant treatment
Seillier, L., Čechová, B., Seillier, A., & Šlamberová, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111368 · Cited by 6
Effects of psilocybin on uncertain punishment learning
Jacobs, D. S., Bogachuk, A. P., Moing, C. L. L., & Moghaddam, B. (2024) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2024.107954 · Cited by 6
Myers, M. G., & Toal, C. B. (1995) · PubMed · Cited by 7
Acute psilocin increased cortical activity in rat
Liu, J., Wang, Y., Xia, K., Wu, J., Zheng, D., Cai, A., Yan, H., & Su, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1593703 · Cited by 5
“EGR1’s reliability is supported by evolutionary conservation and consistent induction by neuronal activity (González-Maeso et al., 2007; Pérez-Cadahía et al., 2011; Leal et al., 2014; Minatohara et al., 2016; Chandra and Lobo, 2017; Duclot and Kabbaj, 2017; Jefsen et al., 2021).”
Brengel, E. K., Axe, B., Maheswari, A., Abeer, M. I., Ortiz, R. J., Woodward, T. J., Walhof, R., Du, W., Utama, R., Rodrigue, B., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10804-w · Cited by 5
Zhao, C.-B.-W., Wei, X.-J., Guo, J., Ding, Y.-S., Luo, J., Yang, X. L., Li, J., Wan, G., Yu, J., & Shi, J. (2022) · Brain Sciences · doi:10.3390/brainsci12050589 · Cited by 5
“Additional targets have been shown to be associated with anxiety disorders, for example, psilocybin, a drug with therapeutic potential for anxiety, which reduces the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) in the hippocampus [50].”
BackgroundSchuler, H., Zhou, D., Savignac, C., Cvetkovska, V., Tse, Y.-C., Meccia, J., Lopez, J., Harutyunyan, A. S., Ragoussis, J., Bzdok, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.08.631940 · Cited by 5
From Policy to Perception: Do Public Views on UK Drug Policy Shape Attitudes Toward Psychedelics?
Dickson, K., Stubbings, D. R., Hurst, M., & Davies, J. L. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2558579 · Cited by 4
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4
Ivan, V. E., Tomàs‐Cuesta, D. P., Esteves, I. M., Luczak, A., Mohajerani, M. H., McNaughton, B. L., & Gruber, A. J. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16558 · Cited by 4
“Higher doses also have stronger effects on plasticity-related genes (Jefsen et al., 2021).”
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
Androni, X., Boyd, R. J., Rosenberg, P. B., & Mahairaki, V. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1605051 · Cited by 4
Zhang, J., Lin, C., Lv, X., Zhao, H., & Wang, X. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.02.011 · Cited by 5
Gattuso, J. J., Bezcioglu, B., Wilson, C., Havaux, K., Hannan, A. J., & Renoir, T. (2025) · Psychedelics. · doi:10.61373/pp025i.0044 · Cited by 3
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions
Iorgu, A.-M., Vasilescu, A.-N., Pfeiffer, N., Spanagel, R., Mallien, A. S., Inta, D., & Gass, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01699-3 · Cited by 3
“We chose the doses of psilocybin according to Jefsen et al. (2021), who used doses up to 20 mg/kg in rats without reporting any adverse effects or mortality [31].”
MethodVella, Y., Syrová, K., Petrušková, A., Koutrouli, I. R. A., Kútna, V., Pala, J., Nikolič, M., Šíchová, K., Mazoch, V., Jurok, R., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338232 · Cited by 3
“In contrast to our study, 90-min psilocybin treatment did not exhibit any significant changes in Arc in the PFC, but decreased expression in the hippocampi of rats (Jefsen et al., 2021).”
Psychedelics: Old drugs, new trips
Rucker, J., & Seth, P. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211003495 · Cited by 3
“Further downstream, Jefsen et al. (2021) investigate the acute effects of psilocybin on the expression of 46 neuroplasticity related genes in the prefrontal cortex and hippocampi of rats, showing rapid expression in plasticity promoting genes, more so in the prefrontal cortex (where 5-HT2A is…”
BackgroundWang, Y., Yao, Y., Su, R., & Yan, H. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70307 · Cited by 3
“Intriguingly, recent studies suggest that psyche-delics can alter neuronal activity, gene transcription levels, and changes in synaptic plasticity in the prefrontal cortex of rodents (Jefsen et al., 2020; Olson, 2022).”
Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs
Ippolito, A., Tiranti, A., Hurley, S., Gilmour, G., Churchill, G. C., & Sharp, T. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00138 · Cited by 3
Uso da psilocibina no tratamento de transtornos psiquiátricos: Revisão da literatura
Teixeira, G. B., Passos, A. C. D. B., Farias, B. V., Girão, A. B. C. F., Marçal, L. D. S., Albuquerque, K. O. D. S., & Ferreira, M. A. D. (2024) · Research Society and Development · doi:10.33448/rsd-v13i2.44971 · Cited by 4
Potencial terapéutico de la psilocibina en neuropsiquiatría: una revisión narrativa
Faccini-Durán, G. (2025) · Acta neurológica colombiana · doi:10.22379/anc.v41i3.1922 · Cited by 2
Gudmundsen, F., Czurylo, J., Vo, C. T., Ruuska, J., Jessen, N. S., Baun, C., Herth, M. M., Shalgunov, V., Fisher, P. M., & Palner, M. (2024) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/mq4v2 · Cited by 2
Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathwaysPreprint
Barnett, J. H., Todd, K. T., Benetatos, J., Rabichow, B. E., Gibson, K. A., Olney, K. C., & Fryer, J. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628764 · Cited by 2
Mennenga, S. E., Hanson, T., Semple, M. G., Lifshitz, D., Flores, B., Balducci, J., Harker, S. A., Ford, A., & Lewis, C. R. (2025) · Research Square · doi:10.21203/rs.3.rs-7890051/v1 · Cited by 2
Metadata
- Authors
- Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K.
- Affiliations
- Aarhus University (DK)
- Corresponding author
- Jefsen, Oskar Hougaard
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-11-04
- Volume
- 35
- Issue
- 4
- Pages
- 483-493
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3094714065
- Semantic Scholar
- bed49b948ad75bafb93f76f7d68ec15f3dd554c7
- Cited by
- 127
- References
- 71
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 31 · 2023: 20 · 2022: 11 · 2021: 16 · 2020: 1
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Det Frie Forskningsråd (DFF-7025-00041)
- Solar Fonden af 1978
- Fonden til Lægevidenskabens Fremme
- Direktør Emil C. Hertz og Hustru Inger Hertz Fond
- Dagmar Marshalls Fond
- Torben og Alice Frimodts Fond
- Lundbeckfonden (R-197-2016-1730)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psilocybin, psychedelics, transcriptional regulation, prefrontal cortex, hippocampus, immediate early genes, neuroplasticity, gene expression, mRNA translation, SGK1, MKP-1, Arc, CLK1, dose-dependent effects, serotonergic psychedelics
- MeSH terms
- Animals, Cytoskeletal Proteins, Dose-Response Relationship, Drug, Gene Expression Regulation, Hallucinogens, Hippocampus, Nerve Tissue Proteins, Neuronal Plasticity, Psilocybin, Genes, fos, Rats, Sprague-Dawley, Prefrontal Cortex, Genes, Immediate-Early, Rats, Early Growth Response Protein 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.